Skip to main content

Table 4 Network meta-analysis results for time to progressiona

From: Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages

Time to progression confirmed at 3 months

Drug

SUCRA

IFN β-1a 44 μg SC thrice weekly

PegIFN β-1a 125 μg every 2 weeks

IFN β-1a 22 μg SC thrice weekly

IFN β-1a 30 μg IM weekly

GA 20 mg daily

IFN β-1b 250 μg SC every other day

Placebo

GA 40 mg SC thrice weekly

IFN β-1a 44 μg SC thrice weekly

0.77

 

1.01 (0.59, 1.74)

0.92 (0.65, 1.30)

0.86 (0.62, 1.19)

0.82 (0.56, 1.22)

0.81 (0.53, 1.22)

0.63 (0.46, 0.86)

Not included in this analysis

PegIFN β-1a 125 μg every 2 weeks

0.75

  

0.91 (0.52, 1.59)

0.85 (0.49, 1.46)

0.81 (0.49, 1.34)

0.80 (0.47, 1.34)

0.62 (0.40, 0.97)

IFN β-1a 22 μg SC thrice weekly

0.62

   

0.94 (0.62, 1.42)

0.90 (0.59, 1.36)

0.88 (0.57, 1.36)

0.68 (0.49, 0.96)

IFN β-1a 30 μg IM weekly

0.5

    

0.96 (0.65, 1.42)

0.94 (0.62, 1.43)

0.73 (0.53, 1.00)*

GA 20 mg daily

0.44

     

0.98 (0.78, 1.24)

0.76 (0.60, 0.97)

IFN β-1b 250 μg SC every other day

0.39

      

0.78 (0.59, 1.02)

Placebo

0.02

       

Test for inconsistency (χ2, df, p)

0.35, 2, 0.84

      

Time to progression confirmed at 6 months

Drug

SUCRA

IFN β-1b 250 μg SC every other day

PegIFN β-1a 125 μg every 2 weeks

IFN β-1a 44 μg SC thrice weekly

IFN β-1a 30 μg IM weekly

GA 20 mg daily

Placebo

PegIFN β-1a 125 μg every 2 weeks

GA 40 mg thrice weekly

IFN β-1b 250 μg SC every other day

0.9

 

0.74 (0.32, 1.71)

0.71 (0.32, 1.60)

0.50 (0.29, 0.87)

0.42 (0.21, 0.83)

0.34 (0.18, 0.63)

Not included in this analysis

PegIFN β-1a 125 μg every 2 weeks

0.71

  

0.97 (0.40, 2.33)

0.68 (0.35, 1.31)

0.56 (0.28, 1.15)

0.46 (0.26, 0.81)

IFN β-1a 44 μg SC thrice weekly

0.7

   

0.70 (0.39, 1.25)

0.58 (0.27, 1.27)

0.47 (0.24, 0.93)

IFN β-1a 30 μg IM weekly

0.4

    

0.83 (0.49, 1.41)

0.68 (0.49, 0.94)

GA 20 mg daily

0.25

     

0.82 (0.53, 1.26)

Placebo

0.05

      

Test for inconsistency (χ2, df, p)

0.77, 1, 0.38

     
  1. aFindings are presented as HR (95% CI)
  2. IFN interferon, GA glatiramer acetate, IM intramuscular, SC subcutaneous, SUCRA surface under the cumulative ranking curve